Woodlands International Research Group
Welcome,         Profile    Billing    Logout  
 0 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Team, Recruitment
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease

Active, not recruiting
2
540
Europe, Canada, US
sabirnetug, Placebo
Acumen Pharmaceuticals
Alzheimer Disease
10/26
10/26
OUTLAST, NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

Terminated
2
61
US
IXT-m200, Placebo
InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)
Methamphetamine-dependence, Methamphetamine Abuse
09/23
11/23
NCT06562114: A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment

Recruiting
1
72
US
TML-6 Granules, Placebo
Merry Life Biomedical Co., Ltd.
Healthy
04/25
07/25
Konis, George
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Completed
3
464
Europe, US, RoW
SEP-363856 75mg, SEP-363856 100mg, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.
Schizophrenia
06/23
06/23
NCT05773846: A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain

Completed
3
428
US
Ropivacaine
PainReform LTD, Lotus Clinical Research, LLC
Bunion
07/24
08/24
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Active, not recruiting
2
350
US
LB-102
LB Pharmaceuticals Inc.
Schizophrenia
12/24
05/25
OUTLAST, NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200

Terminated
2
61
US
IXT-m200, Placebo
InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)
Methamphetamine-dependence, Methamphetamine Abuse
09/23
11/23
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Completed
1
31
US
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
09/23
09/23
NCT05542264: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Completed
1
19
US
SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
02/24
02/24
NCT05463770: A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

Completed
1
15
US
SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
08/23
08/23
NCT05848700: A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Completed
1
60
US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
03/24
03/24
Thomas, Polina
No trials found

Download Options